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Parkinson’s disease (PD) is the second most common progressive neurodegenerative condition 
after Alzheimer’s Disease. It is characterized by a progressive loss of dopaminergic neurons in 
the substantia nigra region of the brain. Symptoms and signs manifest as motor disorders 
affecting balance and physical capacity, and non-motor symptoms such as cognitive decline and 
mood disorders. People with PD face considerable difficulties coping with associated physical 
and psychological changes that affect their quality of life. The main form of treatment is 
pharmacological, which alleviates some of the symptoms but does not slow the progression of 
the disease. Creatine monohydrate (Cr) may have therapeutic benefits in conditions where 
energy dysfunction and high rates of apoptosis are present. Cr supplementation may provide a 
protective effect by augmenting cytosolic high energy phosphate stores, thereby prolonging the 
survival of ‘at risk’ cells of neurodegenerative diseases. Emerging evidence suggests 
supplementation may offer specific benefits in the treatment of mood disorders associated with 
PD. Many different types of exercise improve physical capacity, balance, and quality of life. 
Research has recently demonstrated the potential benefits in PD of diverse modes of exercise, 
such as aquatic exercise and boxing. Combining exercise with Cr supplementation can enhance 
exercise induced muscular strength and power adaptations and may further improve exercise 
capacity and neuromuscular function. This review will critique evidence relating to the potential 
efficacy of Cr supplementation and exercise as a putative therapeutic approach in the treatment 
of the physiological and psychological challenges presented by PD. 
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1. INTRODUCTION 
 
Parkinson’s disease (PD) is the second most common 
degenerative neurological disorder after Alzheimer’s 
disease (43). This complex, multi-layered disease has 
large individual variations in severity and symptoms. 
The primary pathology  involves central dopaminergic 
neuronal loss, causing distal neurological dysfunction 
in skeletal muscle (99). 
Cardinal motor signs and symptoms manifest as 
bradykinesia, tremors, rigidity, postural instability, and 
dyskinesia (79). Co-morbidities, including cognitive 
decline and depression (86), may be present in ~40-
50% of patients; these numbers increase with greater  
 
disease severity (107, 125) and advanced age at 
disease onset (104). 
The causes of PD are not fully understood; however, 
environmental toxins and genetic susceptibility are 
implicated (28, 42).  Interference with complex I 
activity of the mitochondrial electron transport chain 
increases oxidative stress and augments the death of 
the dopaminergic neurons in the substantia nigra pars 
compacta (1, 14, 43, 76, 145). In addition, there is 
characteristic accumulation of abnormal proteins 
known as Lewy Bodies in the surviving neurons (24, 
51, 64). In familial and idiopathic PD conditions, 
increased accumulation of the protein α-synuclein in 
dopaminergic neurons in the substantia nigra may 
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augment apoptosis via an increase in reactive oxygen 
species (ROS) initiated by endogenous dopamine 
metabolism (143).   
Surface electromyography (EMG) studies demonstrate 
that people with PD have slower extension movements 
compared to flexion, whereas individuals without PD 
show no significant difference between extension and 
flexion movements (116). Typically, increased and 
inappropriate co-contraction of agonist and antagonist 
muscle groups contribute to joint stiffness and rigidity, 
which results in energy inefficient and impaired 
movements (92). 
Currently, there is no cure for PD: drug therapy is the 
main line of treatment, which alleviates some of the 
symptoms but has no effect on the deterioration of the 
condition over time. Indeed, therapies that slow the 
progression of this disease have not yet been found. 
Greater drug doses are required as the disease 
progresses, but after 5 years of treatment, dyskinesia 
and ‘freezing’ episodes worsen in ~40% of patients 
(64). The development of adjuvant interventions that 
could ameliorate the symptoms of PD would represent 
a major breakthrough. 
 
2. CREATINE 
 
Creatine (Cr), or methyl guanidine acetic acid, is a 
nitrogenous compound synthesized from the amino 
acids arginine, glycine, and methionine (16). The role 
of Cr is pivotal in the transfer of high energy 
phosphate bonds; it is phosphorylated by the enzyme 
creatine kinase (CK) to form phosphocreatine (PCr), 
which can rapidly re-phosphorylate adenosine 
diphosphate (ADP) to adenosine triphosphate (ATP) 
(139). This reversible reaction facilitates short 
duration high intensity muscular activity (25); in 
addition, Cr shuttles energy from the mitochondria to 
the cytosol in tissues such as brain and skeletal 
muscle, which have high and fluctuating energy 
demands (139). When the demand for energy is very 
high, rapid hydrolysis of PCr increases the Cr 
concentration of the cytoplasm. Cr diffuses to the 
mitochondria through the concentration gradient 
present in the cytoplasm, where the subsequent 
interaction of Cr with mitochondrial CK is 
instrumental in up-regulating mitochondrial oxidative 
phosphorylation (96). Consequently, the importance of 
Cr in the regulation of cellular energy metabolism is 
evident. 
An average 70kg adult has a total Cr pool of ~ 120g, 
comprised of ~40% free creatine and ~60% PCr (46). 
Cr at a rate of 1-2%, and PCr at a rate of 6%, are 
continuously degraded to creatinine by non-enzymatic 
reactions and excreted in urine (103). Daily 
replenishment of the total Cr pool is achieved 
endogenously via the liver and pancreas (~1g) and 
ingested from food sources, predominantly fish and 
meat (~1g) (15).  
 
3. CREATINE SUPPLEMENTATION 
 
Supplementation with creatine monohydrate has been 
used extensively for two decades.   A number of 
studies demonstrate improvements in high intensity 
short duration exercise, strength, power, and work 
performed (30, 70, 82, 90, 136). The ergogenic effects 
of supplementation are thought to be from increasing 
formation of muscle Cr and PCr levels (74, 80), 
leading to improved ATP turnover during intermittent 
high intensity muscle contraction and accelerated ATP 
resynthesis during periods of recovery (68). 
Approximately 20-30% of individuals do not 
experience any effects from Cr supplementation and 
are referred to as non-responders (69). Non-responders 
are proposed to be individuals whose muscular Cr 
stores are optimal and no further increase is 
physiologically possible (67, 74). However, some 
studies report no improvement in performance tests 
despite an increase in intramuscular Cr levels (60, 100, 
124).  Wide ranges in study populations, 
methodologies, and statistical interpretations might 
contribute to the considerable variation found in 
response to Cr supplementation (53, 87). 
 
3.1. Creatine Supplementation as a Therapeutic 
Agent 
 
Supplementation may be of greatest benefit to clinical 
populations in which direct and indirect energy 
deficits contribute markedly to the pathology of the 
disease; specifically, conditions featuring neuronal 
loss, muscle atrophy, and/or fatigue. For example, 
supplementation has resulted in significantly improved 
exercise capacity and functional performance in heart 
failure. Supplementation is rationalised in this disease 
due to impaired muscle cell metabolism, low oxidative 
capacity, and a reduction in total creatine content of 
skeletal muscle; as a result, patients experience 
exertional fatigue (7). A randomised crossover design 
with 13 participants taking 20g of Cr per day for 6wks 
showed no change in aerobic capacity, anaerobic 
threshold, or the 6 minute walk test. However, a 15% 
increase in elbow flexor muscle strength did occur 
(91). Furthermore, Gordon et al. (65) reported a 10-
20% increase in leg muscle strength and endurance in 
heart failure patients after taking a dose of Cr of 20g 
per day for 1wk. Twenty grams for 5 days 
significantly increased contractions in the forearm 
(75% maximal voluntary contraction), with 
improvements in muscle metabolism demonstrated by 
a significant reduction in the formation of ammonia 
(6). Presently, it is unknown if Cr supplementation can 
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directly influence cardiac performance, but it is 
suggested that potential for this may be limited (59).  
In a cardiac rehabilitation group, no additional benefits 
were gained from Cr supplementation in conjunction 
with exercise. This may in part have been due to the 
large initial benefits of exercise, which included 
resistance training, overwhelming the potentially 
modest additional benefits of Cr (37). Similarly, no 
improvement in exercise capacity has been found in Cr 
supplemented chronic obstructive pulmonary disease 
(COPD) rehabilitation (2, 44, 61), despite 
improvements in peripheral strength and muscular 
endurance (61); however, no large scale clinical trials 
have been conducted. 
In idiopathic myopathies, low levels of PCr and 
intracellular calcium leakage can exacerbate 
excitotoxicity (73). Chung et al. (34) reported a 
placebo controlled 6 month supplementation 
(20gm/day for 8 days followed by 3gm/day for the 
remaining period) in conjunction with a home-based 
exercise regimen; this improved both the ability to 
sustain repeated bouts of high intensity exercise (e.g., 
stair climbing and descent, sit to stand, and walking 
challenges) and measures of endurance capacity 
(functional index in myositis). Metabolic myopathies 
have not shown any beneficial effects from 
supplementation (87), possibly due to defects in 
creatine uptake in the muscle (71). Muscle myopathies 
have many subgroups and phenotypes with high 
variation in pathology; this presents complex 
scenarios, particularly as the majority of studies are 
parallel in design with small participant numbers. 
Similarly, the effectiveness of Cr in Amyotrophic 
lateral sclerosis (ALS) remains under scrutiny. ALS is 
a progressive neuromuscular disease causing 
weakness, dysfunctional muscle control, and paralysis. 
High levels of glutamate in this condition are 
neurotoxic and cause excitotoxicity, which leads to 
increased levels of reactive oxygen species. Resulting 
free radical damage augments oxidative damage and 
contributes to mitochondrial dysfunction; 
subsequently, motor neurons die, leading to 
progressive muscle weakness (26). Other 
neurodegenerative conditions, such as HD and PD, 
also feature these characteristics (32). A review by 
Ellis et al. (89) examined the findings of animal and 
clinical research into Cr supplementation in ALS. The 
authors found that, despite problems with recruitment, 
study design, and inconclusive results regarding 
effectiveness, Cr does show potential to protect 
vulnerable neurons and improve physical ability.  
In Chung’s (34) study, exercises were home-based and 
resulted in improvements in functional activities; 
whereas in Cornelissen’s (37) cardiac rehabilitation 
study, physical measurement outcomes consisted of a 
graded cycle test and isometric and isokinetic knee 
extension strength and endurance. A study comparing 
exercise and supplementation with exercise alone in 
PD patients found that although knee extension 
strength improved similarly in both groups, only the 
Cr group improved in the functional sit to stand test 
(75). This highlights the impact study design 
variations can have on findings and suggests 
functional measures of physical performance should 
be included in testing parameters in non-athletic and 
clinical populations.  
The benefits of supplementation may extend beyond 
enhancements in skeletal muscle performance. Brain 
function, such as memory accumulation and recall, is 
energy dependant (106). As such, Cr supplementation 
may be beneficial in conditions of increased metabolic 
demand; for example, in the aging brain (101). 
Improvements in simple cognitive performance tests in 
the elderly occurred after 20g of Cr per day for 2 
weeks (101). The authors hypothesised that reductions 
in excitotoxicity and increased neuroprotection may 
have facilitated these improvements. Furthermore, 
depressive states have responded favourably to 
supplementation [see section 4.1] (4, 71, 118).  
The effects of Cr in Huntington’s disease (HD) are 
equivocal at present. Animal models of Cr 
supplementation show improvements in brain atrophy, 
reductions in intranuclear inclusions (5, 45, 58), and 
biomarkers of HD pathology (144). Despite these 
encouraging findings, clinical trials have found no 
changes in disease status (137); however, 
administration of 8-10 weeks of Cr supplementation 
did result in a reduction in glutamate and glutamine in 
the brain of HD patients. This suggests Cr may reduce 
levels of excitotoxicity, which are abnormally high in 
HD, warranting further investigation (17). The 
CREST-E clinical trial currently underway in the U.S. 
is evaluating the safety, tolerability, and effectiveness 
of large doses (up to 40g/day) in slowing the 
progression of functional decline in HD. 
Despite variable results, and at times speculative 
theories surrounding the potential therapeutic benefits 
of Cr supplementation in clinical populations, a 
number of conditions, particularly those featuring high 
levels of oxidative stress, vulnerable neurons, and 
energy depletion, may benefit from Cr 
supplementation. 
 
3.2. Creatine Supplementation and 
Neurodegenerative Disease 
 
The brain accounts for 2% of total body mass, whilst 
using 20% of its total resting energy output (72). Cr is 
required to meet high energy demands; mental 
retardation and neurological dysfunction may develop 
in conditions of significant Cr deficiency (6). Many 
neurodegenerative conditions share similar 
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biochemical pathological characteristics, including 
energy dysfunction and depletion, increased oxidative 
stress, excitotoxicity, and mitochondrial dysfunction. 
Mitochondrial dysfunction appears to play a central 
role in some of the most common neurodegenerative 
diseases (43), leading to abnormally high rates of 
apoptosis (1) and accelerating loss of specific neurons 
(13).   
Exogenous supplementation may increase endogenous 
Cr levels and provide greater energy supply to cells by 
augmenting cytosolic high-energy phosphate stores, 
thereby exerting a protective effect and prolonging the 
survival of ‘at risk’ cells (27). Cerebral creatine 
deficiency disorders (CCDs), such as X-linked 
creatine transporter deficiency (SLC6A8 deficiency), 
which causes mental retardation, speech and language 
delay, and epilepsy, highlight both the importance of 
adequate Cr levels in the brain and the central role of 
the creatine transporter in maintaining Cr levels in the 
CNS (126). Clearly, this transport system will be 
saturable and so the scope for exogenous 
supplementation may be limited in situations where no 
Cr deficiency is present but such supplementation 
would at least ensure saturation of the transport 
system. Studies have shown that an increase in brain 
Cr level is possible following supplementation (3).  
Whether or not creatine has a direct effect on the 
pathology of PD is unknown. More likely, it exerts its 
influence via enhanced bioenergetics, helping make 
cells more resilient to damaging environments. Cr 
supplementation may, therefore, extend the survival of 
cells; however, progression of the neurodegenerative 
disease will likely still occur (27, 142). As yet 
unknown is whether or not long term Cr 
supplementation down-regulates endogenous Cr 
synthesis. 
 
3.3. Creatine as an Adjuvant Therapy in Parkinson’s 
Disease 
 
In vitro and animal studies demonstrate the 
neuroprotective capacity of Cr supplementation 
against neurotoxicity (88, 98) and the attenuation of 
motor symptoms in models of PD (133). Animal 
studies have generated potentially promising data; 
however, species-related differences make 
extrapolation of results from animal models to 
meaningful clinical improvements in humans complex. 
Bender and colleagues (18) conducted a 2 year, 
double-blind, placebo-controlled pilot study with 60 
PD subjects (Hoehn and Yahr Scale ≤ 2.5). Subjects 
were supplemented with 20g of Cr per day or placebo 
for 6 days, followed by 2g per day for 6 months and 
4g per day for the remainder of the 2 year period.  
Single-photon emission computed tomography 
(SPECT) was used to measure the extent and degree of 
dopaminergic nerve cell loss from baseline to the end 
of the study period. Supplementation was well 
tolerated by the subjects in the Cr group; however, it 
had no significant effect on SPECT variables or total 
Unified Parkinson’s Disease Rating Scale (UPDRS) 
scores when compared to the placebo group. 
Importantly, a significant effect (P = 0.046) occurred 
in the UPDRS subscale ‘depression’ in the Cr group, 
suggesting a positive improvement in mood state as a 
result of supplementation. The Cr group also had a 
significantly (P < 0.05) smaller dose increase in 
dopaminergic therapy at the end of the trial (18), 
which implies a possible benefit to disease status that 
may not have been detected by the techniques used in 
this study. 
A randomized, double blind, futility clinical trial in 
early PD assessed the ability of Cr to alter the 
progression of PD relative to a pre-determined 
threshold. Subjects ingested 2 x 5 g Cr or placebo per 
day and a baseline UPDRS score was recorded and re-
evaluated at 1, 3, 6, 9, and 12 months. The mean 
change in disease status for the Cr group from baseline 
to either 12 months or the commencement of 
symptomatic treatment was 5.6 (SD 8.69); this was 
lower than the pre-determined threshold value of 7.46 
(30% less than the expected change). As a result, Cr 
supplementation could not be rejected as futile. 
Supplementation was well tolerated by the subjects 
with 91% compliance, and none reported serious side 
effects (132). 
Subsequently, a Phase III clinical trial by The National 
Institute of Neurological Disorders and Stroke 
Exploratory Trials in Parkinson’s Disease (NINDS 
NET-PD) commenced in 2007 (21). The aim of this 
study was to evaluate the efficacy of Cr 
supplementation (10g/day) in a cohort (n = 1741) of 
individuals in the early stages of PD, who had been 
receiving dopaminergic treatment ≤ 2years. The 
primary outcome measurement was to determine if 5 
years of Cr supplementation slows the progression of 
PD to a greater degree than standard drug therapy 
alone.  In addition, the safety and tolerability of long-
term supplementation would be assessed.      
A Global Statistical Test (GST) model was applied in 
September 2013 by the researchers to determine the 
efficacy of the Cr treatment in reducing overall 
changes in disease state. This was necessary to justify 
continuation of the clinical trial. The analysis found no 
significant difference between the treatment and 
placebo groups. A finding of futility was declared and 
the trial was terminated (105).  In other words, 5 years 
of supplementation statistical testing suggested that no 
significant difference in disease progression existed 
between the treatment and placebo groups. The five 
measure GST model selected encompasses overall 
disease status changes. This increases the power of 
detection when any treatment effect occurs across all 
measurement domains; however, power is lost if a 
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single measure demonstrates change. Under such 
conditions differences may not be detected, and 
individual aspects of the efficacy of supplementation 
could be present but not be detected (81).  
Although this finding is disappointing, this study 
crucially provides important information regarding the 
tolerability and safety of long term Cr supplementation 
in PD. Evidence from animals studies suggests that 
there are relatively low concentrations of creatine 
transporters in the substantia nigra area of the brain, 
which could limit the potential for Cr to slow the 
progression of the disease (97). Future publication of 
the full findings of this clinical trial should inform 
other studies examining Cr supplementation in 
neurological disorders.    
 
3.4. Antioxidant Effects of Creatine 
 
Free radicals and reactive oxygen species can impair 
protein turnover (113) and augment muscle fatigue 
(93). In vivo experiments suggest Cr may have 
antioxidant properties (93), thereby providing some 
level of protection from the deleterious effects of 
increased levels of oxidative stress and fatigue 
associated with PD (62). Cr may augment antioxidant 
and neuroprotective effects by enhancing cytosolic 
high energy phosphates that maintain ATP levels 
under high oxidative stress conditions (130) (see 
Figure 1). 
Figure 1: Mitochondrial dysfunction in Parkinson’s Disease. 
Adapted from Adhihetty and Beal. Creatine and its potential 
therapeutic value for targeting cellular energy impairment in 
neurodegenerative diseases. Neuromolecular Medicine 2008; 
10 p23 Fig.3. Springer/Kluwer Academic Publishers with 
kind permission of Springer Science and Business Media 
(12). 
             
        
Kingsley et al. (84) reported that supplementation in 
conjunction with 5 days of endurance exercise in 
healthy males had no effect on oxidative stress levels. 
However, Bloomer et al. (22) reported 8 weeks of 
resistance training reduced oxidative stress in subjects 
with PD. Endurance exercise cannot be directly 
compared to resistance training; however, this study 
provides evidence that the oxidative status of people 
with PD can be altered and suggests a longer time 
frame may be necessary to observe adaptations. The 
effect of supplementation on oxidative status in human 
PD trials has not been evaluated. 
 
 3.5. Creatine and Musculoskeletal Abnormalities in 
Parkinson’s Disease 
 
Motor dysfunction is primarily related to central 
dopamine depletion; however, histological studies 
suggest pathology may not be restricted to the brain 
(141). Individuals with PD can also have 
musculoskeletal mitochondrial abnormalities, 
inflammatory myopathies, and necrotizing myopathies 
with no obvious link established between these 
pathologies and adverse drug side effects (63, 141). 
Therefore, increased free radical damage in PD may 
have a direct effect on skeletal muscle mitochondria 
(141). 
A reduced capacity for muscle torque and force 
production associated with a prolonged muscle 
relaxation time (36) and lower levels of EMG activity 
during isometric voluntary contractions (119) are 
common in PD. Longer EMG relaxation times have 
been linked to more pronounced bradykinesia (66). 
Whether extended muscle relaxation time is directly 
related to the pathology of the disease or due to drug 
related side effects is unknown. 
Five days of Cr supplementation improved 
neuromuscular function in moderately trained healthy 
men (12). Peak torque (PT) increased 33.4% (P < 
0.05) more in the Cr group than in the placebo group, 
whilst time to reach PT in the Cr group decreased 
54.7% (P < 0.05) more than the placebo group. 
Measured maximal torque was significantly increased 
at the highest angular velocities (180o·s-1 and 240o·s-
1). Conduction velocity increased 15% (P < 0.05) in 
the Cr group at all velocities, remaining unchanged in 
the placebo group, and with no changes reported in 
measures of fatigue in either group (12).  
Supplementation has been shown to decrease muscle 
relaxation periods in healthy individuals during 
isometric contractions (134). A decrease in muscle 
relaxation time may reduce energy expenditure, reduce 
co-contraction activity, and increase cross-bridge 
cycling efficiency, potentially improving muscle 
power during rapid repetitive maximal muscle 
contractions with no pause between contractions 
(134). The proposed mechanism for decreased muscle 
relaxation time is via an improvement in calcium 
(Ca2+) kinetics, enhancing muscle contractile 
properties (12, 134) (see Figure 2). There may be 
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potential for Cr to improve neurological function in 
individuals with PD; however, to date no studies 
evaluating the effect of Cr on neurological function in 
PD have been published. 
Interestingly, although considered a pathological 
manifestation in PD, prolonged muscle relaxation time 
is regarded as a mechanism that delays fatigue during 
isometric contractions in healthy muscle (96). In PD, 
this may be an adaptive condition that paradoxically 
results in energy inefficient states during dynamic 
movements, whilst fatigue in postural muscles is 
reduced. 
 
 
Figure 2: Muscle Cell and Potential Sites of Action for 
Creatine Supplementation. Adapted from Powers et al. 
Reactive oxygen and nitrogen species as intracellular signals 
in skeletal muscle, The Journal of Physiology 2011; 589, 
with kind permission of John Wiley and Sons (113). 
 
4. MOOD DISORDERS IN PARKINSON’S 
DISEASE   
 
Mood disorders affect most people with PD at some 
stage in the progression of the disease, the most 
prevalent being depression, anxiety, and apathy (127). 
Depression is considered to be the most common 
mood disorder symptom in PD (39), with an incidence 
of ~35%; however, this figure may be as high as 90% 
in some sub-groups (49). Silverman and Henry (122) 
propose similarities between common symptoms in 
PD and those of depression; e.g., slowness in 
movement, blank expression, stooped posture, and 
slowness in cognitive function could lead to 
overdiagnosis of depression.  In contrast, other authors 
suggest these similarities may lead to confusion and a 
prevalence of underdiagnosis (121). Subtle 
symptomatic differences in PD patients and non-
Parkinson’s populations diagnosed with clinical 
depression mean that the use of valid assessment tools 
are essential when investigating depression in PD. 
Additionally, depression in PD is often accompanied 
by anxiety disorder (140). The prevalence of anxiety 
in PD is estimated between 40-60% (115); cognitive 
dysfunction and anxiety are not related in PD. 
Approximately 17-70% of individuals with PD have 
symptoms of apathy (111). Those with this condition 
experience low motivation, lethargy, difficulty 
completing tasks, and a high incidence of fatigue 
(127). The incidence of apathy can be related to 
depression, but can also occur independently (85). 
Disease status is related to the presence of clinical 
depression in PD (110). Impairment of activities of 
daily living (ADL) is more strongly associated with 
depression than specific motor symptoms (129), 
meaning the overall impact the disease has on an 
individual’s quality of life and well-being presents the 
greatest difficulty. This is closely related to the 
person’s own perception of having poor health and 
low quality of life; in fact ‘illness belief’ can predict 
psychological outcomes in PD (123).  
The causes of mood disorders in PD are not 
completely understood; they are thought to result from 
a complex interaction between psychological and 
neurobiological processes (127). An organic origin is 
evidenced by early presentation of symptoms in a 
significant number of individuals long before 
manifestation of motor symptoms and diagnosis of PD 
(77). Genetic variations in a serotonin transporter gene 
implicate inherited aspects of PD mood disorders in 
some individuals (102). Defects in the neurocircuitry 
(110) of the frontal subcortical region of the brain in 
neurodegenerative diseases are linked to 
neuropsychiatric symptoms that may be directly or 
indirectly implicated in mood disorders (23). These 
neurological abnormalities in PD are hypothesized as 
being linked to dysfunctional neurotransmitters of the 
dopaminergic, serotonergic, and noradrenergic 
systems (127). 
 
4.1. Creatine Supplementation and Mood Disorders 
in Parkinson’s Disease 
 
Recent intriguing evidence examining the potential 
effects of Cr supplementation in a number of 
psychiatric conditions may signal benefits for PD that 
have not yet been fully realized.   A topical review of 
Cr metabolism in psychiatric disorders suggests the 
effect of psychological stress in some of the most 
common mental health conditions, resulting in 
augmented energy demands within the brain. This may 
lead to depletion of total Cr and PCr in the brain and 
subsequent mitochondrial dysfunction, triggering a 
cascade of neurological events that could cause, or 
exacerbate, thought or mood disturbances.       
Emerging evidence suggests neurons may be 
vulnerable to damage in conditions of energy 
imbalance and result in increased oxidative stress. 
Indeed, production of neurotransmitters such as 
dopamine and serotonin may be compromised when 
there is an energy deficit (3). The implications in PD 
are evident.  
Allen (3) examined the potential benefits of Cr 
supplementation in psychiatric conditions such as 
depression and some anxiety disorders. Two weeks of 
Cr supplementation increased brain concentrations of 
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Cr and PCr (20, 95) and may have had the potential to 
improve brain energetics. Enhanced brain metabolism 
could protect vulnerable neurons associated with mood 
and emotion, which may be at risk in psychologically 
stressful conditions present in PD. In addition, Cr 
supplementation may help optimize neurotransmitter 
production, which would be beneficial in depleted 
states. These theories may explain the findings of 
Bender and co-workers (18), who reported an 
improvement in depression scores following Cr 
supplementation without an overall improvement in 
disease status.  Recently, individuals with PD 
suffering from depression benefited from 
supplementation with omega -3 fish oils (39). This is 
encouraging as it provides evidence that people with 
PD respond positively to nutritional supplementation 
targeted to improve mood disorders.   
 
5. EXERCISE AND PARKINSON’S DISEASE  
 
Physical activity levels are likely to be reduced in 
individuals with PD compared to individuals without 
PD due to lower exercise capacity related to metabolic 
inefficiency and earlier onset of fatigue (9). Inactivity 
contributes to increasing disease severity, poor 
walking performance, and more difficulty performing 
the activities of daily life (135). Individuals with PD 
who experience the highest levels of fatigue tend to be 
the most sedentary and possess lower levels of 
functional capacity and physical function (62). 
Sedentary lifestyles are also linked to increased ROS 
production (38), immunosuppression, pathological 
inflammatory conditions, and accelerated brain aging 
(10). A complete understanding of the potential 
benefits of exercise in brain health is emerging (8). 
Erickson et al. (56) reported that moderate intensity 
aerobic exercise 3 days per week for 1 year increased 
hippocampal volume by 2% in adults without 
dementia compared to a control group who only 
performed stretching exercises. Increased hippocampal 
volume is associated with higher serum levels of brain 
derived neurotrophic factor (BDNF), which mediates 
neurogenesis in the brain and usually declines with age 
(56). Evidence suggests that exercise may elevate 
dopamine receptor expression in PD (138) and may 
reduce overall levels of skeletal muscle ROS, despite 
increased ROS production in muscle fibres as a result 
of contraction (38). 
Dynamic, functional, high intensity movements with 
many repetitions and increasingly complex 
movements have successfully increased the UPDRS 
score of 20 patients with mild to moderate PD by a 
clinically significant mean of 5.05 (52). Exercise 
training improves strength, balance, and functional 
capacity and can enhance QOL in individuals with PD 
(47, 48, 52, 57, 120).  Better QOL in PD is associated 
with increased fitness levels, improved social 
interactions, and greater independence (11).  
A variety of exercise modalities are well tolerated by 
people with PD. These include high intensity 
resistance (47, 48) and aerobic training (19, 78). 
Recently, more diverse types of exercise have shown 
efficacy in PD. Tai Chi (94), aquatic exercise (11), and 
boxing training (35) have improved balance, 
functional capacity, and ADL. Music therapy has also 
had positive effects in measures of motor and non-
motor symptoms (50, 109). Low expectations of any 
worthwhile benefits from exercise contribute to poor 
engagement in exercise participation (54) and levels of 
self-efficacy predict whether or not ambulatory 
individuals with PD engage in exercise (55). The fear 
of falling is one of the main barriers to exercise 
reported by people with PD (54); appropriate aquatic 
exercise may increase exercise choice and reduce the 
fear of falling. Longitudinal information regarding 
adherence to exercise in PD from early in the disease 
to later stages is not available, but the information 
available suggests it is crucial to design exercise 
interventions that offer a variety and choice to meet 
the various physical and psychological needs of those 
with PD.  
 
5.1. Exercise and Creatine Supplementation in 
Parkinson’s Disease 
 
Cr supplementation can allow more work to be 
performed during high intensity repetitive exercise 
(30, 31, 70), increase exercise induced muscular 
strength and power adaptations (33, 40), and augment 
lean body mass (136). Combining strength training 
and creatine supplementation up-regulates myogenic 
activity in skeletal muscle and may optimize muscle 
fibre growth more than strength training alone (108). 
Additionally, exercise can augment Cr accumulation 
in exercised skeletal muscle (74), possibly by 
enhancing the Na+-Cr transporter system (117). To 
date there have been no studies published evaluating 
the effect of exercise on brain concentrations of Cr.  
Currently one study has measured the effect of Cr 
supplementation and exercise in PD. Hass et al. (75) 
combined supplementation with resistance training in 
a randomized, double-blind study of twenty subjects (n 
= 17 males, n = 3 females) classified as the Hoehn and 
Yahr scale ≤ 3. Subjects performed one set of 8-12 
reps at 70% of 1RM for the upper and lower body to 
volitional fatigue for 12 weeks; in addition, subjects 
performed one set of leg extension and flexion at 50% 
of 1RM, which allows faster movements to be 
performed.  Load was progressively increased by 5-
10% when subjects were able to perform 12 reps 
during strength training, and 20 reps for low resistance 
power training. Post exercise chest press, leg 
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extension, and bicep curls increased 9%, 16%, and 
18%, respectively, in the placebo group, and 21%, 
18%, and 23%, respectively, in the Cr group. Both 
groups significantly improved leg extension endurance 
(P ≤ 0.05) and increased fat-free mass (P = 0.002); no 
significant differences were found between groups 
(75).  
Combining resistance training and supplementation 
improved muscular strength and endurance compared 
to resistance training alone. Despite an increase in leg 
extension strength, in both groups only the Cr group 
significantly improved the chair stand test. 
Supplementation may have had a greater effect in the 
chair stand test as this test involves repeated high 
intensity movements. In the Cr supplemented group, 
neurological function as well as strength may have 
been improved.  
Cr supplementation - in conjunction with different 
types and intensities of exercise - may augment the 
benefits of exercise alone (see Figure 3). Performing 
high intensity exercise such as boxing, aquatic 
resistance training, deep-water running, or aquatic 
cycling with supplementation may improve training 
effects, which would be transferred to improvements 
in QOL and ADL in PD. Ultimately, real improvement 
in a person’s quality of life is the most important 
aspect, both to PD patients and to their caretakers.  
 
 
Figure 3: Potential Synergistic Relationship between 
Exercise and Creatine Supplementation in Parkinson’s 
Disease. Reactive Oxygen Species (ROS). Oxidative Stress 
(OS). Activities of Daily Living (ADL). Quality of Life 
(QOL). 
 
6. SAFETY OF ORAL CREATINE 
SUPPLEMETATION  
 
No serious adverse effects have been documented as a 
result of short term supplementation (29, 37, 41, 75, 
87), or long term studies of up to 2 years duration (17, 
71, 90, 132), in healthy and clinical populations. 
The most consistently reported side effect of 
supplementation is weight gain of 1-2 kg, which is 
attributed to an increase in intracellular water in 
muscle tissue (80). In an extensive review of safety 
issues and concerns by Wyss et al. (142), evidence of 
muscle cramps, increased thirst, stomach cramps, 
diarrhoea, and rashes have been isolated cases and 
subjective reports. Reports of renal dysfunction linked 
to supplementation have been confined to case studies 
(114, 128, 131). In Pritchard et al. (114) subjects had a 
previous history of renal dysfunction, whilst the 
subject in Thorsteinsdottir et al. (131) had consumed 
multiple supplements in addition to creatine. The 
affected person in Taner et al. (128) had no prior renal 
problems, nor had they reported consuming any other 
supplements; on cessation of supplementation renal 
function returned to normal. Individual case studies 
should not be dismissed, but they lack controls that 
would provide more conclusive evidence. A recent 
comprehensive review concludes Cr supplementation 
does not impair glomerular filtration rate or 
glomerular membrane permeability in healthy or 
neurodegenerative subjects (83). Nevertheless, 
individuals who may have existing renal disease, or an 
increased risk of kidney dysfunction, should be 
regularly monitored (83, 112). 
 
7. CONCLUSION 
 
Parkinson’s disease presents a challenging scenario for 
those directly affected. Additionally, it presents 
complex demands for the scientific community, 
supporting professionals in their quest to elucidate the 
aetiology of the disease and devise the best prevention 
and treatment strategies.  The individual variability of 
the condition and multi-layered symptomatology 
determines that a holistic approach is required. 
Cr is central to the transfer of energy bonds in tissues 
with highenergy requirements. Many 
neurodegenerative diseases, including Parkinson’s 
disease, demonstrate electron pathway pathologies that 
are possible targets for the pleiotropic effects of Cr. In 
vitro and animal models of PD demonstrate that Cr has 
neuroprotective effects, and clinical trials suggest a 
promising impact on mood and disease state.  
Exogenous Cr may augment cytosolic high energy 
phosphate stores, thereby rendering vulnerable cells 
more resistant to environmental stress and prolonging 
their life. The highly specialized energy buffering 
capacity of Cr may protect brain cells from the 
deleterious effects of stressful mood disorders, which 
have been found to deplete endogenous brain Cr 
concentrations. Energy deficiency in specialized brain 
cells may lead to increased oxidative stress conditions 
and reductions in neurotransmitter production. 
Supplementation with omega-3 fatty acids has been 
found to improve depression in PD patients, 
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demonstrating potential efficacy for nutritional 
supplementation strategies in this condition. It is 
hypothesized here that Cr supplementation may offer 
benefits in the treatment of mood disorders in PD.   
Additionally, the ergogenic effects of supplementation 
may improve functional capacity, reduce muscle 
atrophy, and be of specific benefit to PD sufferers. 
Individuals with PD have demonstrated energy 
inefficient and impaired movements associated with 
longer relaxation times. Musculoskeletal 
mitochondrial abnormalities, inflammatory, and 
necrotizing myopathies may also present.  
Supplementation may improve muscle efficiency and 
neuromuscular function by up-regulating Ca2+ 
kinetics and enhancing muscle contractile properties.  
A variety of exercise modalities improves functional 
capacity and quality of life in individuals with PD. 
Greater exercise options should help address particular 
problems associated with engagement in exercise. 
Combining supplementation with exercise may have 
synergistic effects by accelerating Cr uptake and 
augmenting the beneficial effects of exercise alone. No 
serious safety issues have been associated with 
creatine supplementation; however, a greater 
understanding of the optimal application of 
supplementation is necessary to realize the full 
potential of this nutritional supplement.    
Further, well controlled studies are required to 
investigate the potential effects of Cr supplementation 
in mood disorders and assess the combined effects of 
supplementation and exercise on functional capacity 
and QOL in people with PD.    
This review concludes that creatine supplementation, 
particularly in conjunction with exercise, presents the 
potential for a safe, inexpensive, and effective 
adjuvant treatment that may improve quality of life in 
PD. 
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